Better Health,
Brighter Future
Our Products
The current Takeda UK portfolio comprises of the following medicines:
To download a patient information leaflet (PIL) and a summary of product characteristics (SmPC) for each medicine, simply follow the links within the table below:
| If you are concerned about any of the conditions or treatments listed below please consult your General Practitioner or other healthcare professional. | ||
| Actos® - pioglitazone hydrochloride | ||
| Actos 15 mg, 30 mg, 45 mg Tablets | SmPC | PIL |
| Adcetris®▼ - brentuximab vedotin | ||
| Adcetris 50 mg powder for concentrate for solution for infusion | SmPC | PIL |
| Alofisel®▼ - darvadstrocel * |
||
| Alofisel 5 million cells/mL suspension for injection | ||
| Amias® - candesartan cilexetil | ||
| Amias 2 mg, 4 mg, 8 mg, 16 mg, 32 mg Tablets | SmPC | PIL |
| Amitiza®▼- lubiprostone | ||
| Amitiza 24 microgram soft capsules | SmPC | PIL |
| Calcichew® Portfolio - calcium carbonate +/- cholecalciferol | ||
| Calcichew 500 mg Chewable Tablets | SmPC | PIL |
| Calcichew D3 Chewable Tablets | SmPC | PIL |
| Calcichew Forte Chewable Tablets | SmPC | PIL |
| Calcichew D3 1000 mg/800 IU Once Daily Chewable Tablets | SmPC | PIL |
| Calcichew D3 500 mg/400 IU Caplets | SmPC | PIL |
| Calcichew D3 Forte Chewable Tablets | SmPC | PIL |
| Competact® - pioglitazone hydrochloride/metformin hydrochloride | ||
| Competact 15 mg/850 mg film-coated Tablets | SmPC | PIL |
| Condyline® - podophyllotoxin | ||
| Condyline 0.5% w/v Cutaneous Solution | SmPC | PIL |
| Edarbi® - azilsartan medoxomil potassium | ||
| Edarbi 20 mg, 40 mg, 80 mg Tablets | SmPC | PIL |
| Entyvio®▼ - vedolizumab | ||
| Entyvio 300 mg powder for concentrate for solution for infusion | SmPC | PIL |
| Instanyl® - fentanyl citrate | ||
| Instanyl 50, 100 and 200 mcg nasal spray, solution in single-dose container | SmPC | PIL |
| Instanyl 50, 100 and 200 mcg/dose nasal spray | SmPC | PIL |
| Matrifen® - fentanyl | ||
| Matrifen 12, 25, 50, 75, 100 micrograms/hour Transdermal Patch | SmPC | PIL |
| Mepact® - mifamurtide | ||
| Mepact 4 mg powder for suspension for infusion | SmPC | PIL |
| Ninlaro®▼ - ixazomib citrate | ||
| Ninlaro 2.3 mg, 3 mg and 4 mg hard capsules | SmPC | PIL |
| Prostap® SR DCS and Prostap®3 DCS - leuprorelin acetate | ||
| Prostap 3 DCS 11.25 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe |
SmPC | PIL |
| Prostap SR DCS 3.75 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe |
SmPC | PIL |
| Protium® - pantoprazole | ||
| Protium 40 mg i.v. powder for solution for injection | SmPC | PIL |
| Pantoprazole 20 mg gastro-resistant tablets | SmPC | PIL |
| Pantoprazole 40 mg gastro-resistant tablets | SmPC | PIL |
| TachoSil® - human fibrinogen, human thrombin | ||
| TachoSil sealant matrix | SmPC | PIL |
| Vipdomet®▼ - alogliptin and metformin | ||
|
Vipdomet 12.5 mg/850 mg film-coated tablets |
SmPC | PIL |
| Vipidia®▼ - alogliptin benzoate | ||
| Vipidia 6.25 mg, 12.5 mg, 25 mg film-coated tablets | SmPC | PIL |
| *Alofisel is marketed by Takeda UK under license from TiGenix |
|
Please refer to the Summary of Product Characteristics for details on the full side-effect profile and drug interactions of the medicines refered to above. Adverse events should be reported. Reporting forms and information can be found at https:yellowcard.mhra.gov.uk/ |
"The black triangle denotes that additional monitoring is required in relation to adverse reactions. This allows quick identification of new safety information."
UK/WBC/1707/0002d(2)
Date of Preparation: June 2018